
What patient subgroups were studied in the NATALEE Trial?
In the 5-year NATALEE trial follow up, in patients with stage II/III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (eBC) at high risk of recurrence, KISQALI® (ribociclib), in combination with an aromatase inhibitor (AI), consistently improved invasive disease-free survival (iDFS), regardless of stage, nodal status, or menopausal status. Explore the subgroup data below1,2
In the 5-year analysis, iDFS results favored KISQALI across prespecified subgroups, including no nodal involvement
NATALEE: KISQALI + AI vs AI alone at 5 years1
Hazard ratios reported as KISQALI + AI vs AI alone.
aNodal status classification according to AJCC staging. Nodal status is from the most advanced stage derived per surgical specimen or at diagnosis.1
The 5-year subgroup analysis was prespecified and descriptive in nature; as such, there was no prespecified statistical procedure controlling for type 1 error.
iDFS was defined as the time from randomization to the date of the first event of local invasive breast cancer recurrence, regional invasive recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer (excluding basal and squamous cell carcinomas of the skin), or death (any cause).2
NATALEE was a randomized, multicenter, open-label, phase III study of KISQALI + letrozole or anastrozole (n=2549) vs letrozole or anastrozole (n=2552) for the adjuvant treatment of men and women with stage II/III HR+/HER2- eBC, including all those with node-positive or high-risk node-negative disease (eligible stages and nodal status include: anatomic stage group IIB-III, or anatomic stage group IIA that is either node positive, or node negative with histologic grade 3, or histologic grade 2 with Ki-67 ≥20% and/or high risk by gene signature testing). At a median follow-up of 33.3 months, with 509 iDFS (primary end point) events in the study (226 [8.9%] in the KISQALI arm and 283 [11.1%] in the NSAI-alone arm), iDFS at the 3-year landmark was 90.7% for KISQALI + NSAI vs 87.6% for NSAI alone (absolute difference 3.1%); there was a 25.1% relative reduction in the risk of an iDFS event; HR=0.749 (95% CI: 0.628-0.892).2-4
In the NATALEE trial, KISQALI consistently helped reduce the risk of recurrence in the broadest range of patients, including those with no nodal involvement |

Explore the KISQALI patient profiles
Identify eligible patients like Jasmine, Erin, and Katrice today

